Clinical Trials Logo

Filter by:
NCT ID: NCT05316519 Terminated - Motor Disorders Clinical Trials

Transcutaneous Auricular Vagus Nerve Stimulation to Enhance Motor Learning

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Vagus nerve stimulation (VNS) activates neural pathways leading to the release of chemicals that promote plasticity and learning. Previous work has shown that the auricular branch of the vagus nerve innervates landmarks on the external ear. Work from the PI's laboratory has shown that electrical current applied to the external ear activates neural pathways implicated in the therapeutic effects of VNS. The broad objective of this project is to better understand physiological mechanisms that are modulated by auricular stimulation and its potential to enhance motor learning.

NCT ID: NCT05315908 Terminated - Obesity Clinical Trials

COVID-19 Testing in Underserved and Vulnerable Populations

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to enhance COVID-19 testing in three regional community health centers (CHCs) in San Diego County, California. In collaboration with CHC partners, their consortium organization, Health Quality Partners (HQP), investigators are pursuing the following Specific Aims: 1) Compare the effectiveness of automated calls vs text messaging for uptake of COVID-19 testing among asymptomatic adult patients with select medical conditions and those 65 years of age and older receiving care at participating CHCs. Secondarily, investigators will invite all study participants to receive flu vaccination and will assess feasibility and acceptability of study participants to refer adult family household members who are essential workers for COVID-19 testing. 2) Gather patient, provider, CHC leadership, and community stakeholder insights to establish best practices for future scale-up of COVID-19 testing sustainability and vaccination.

NCT ID: NCT05315479 Terminated - Post Operative Pain Clinical Trials

Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery

Start date: February 24, 2022
Phase: Phase 4
Study type: Interventional

This study is an open-label, multicenter evaluation of Safety and Pharmacokinetics of N1539 in postoperative Pediatric subjects aged 2 to <17 years.

NCT ID: NCT05314868 Terminated - Clinical trials for Congenital Heart Disease

Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in Cardiac Repair or Reconstruction Surgery

Retro-C
Start date: March 31, 2022
Phase:
Study type: Observational

The objective of this postmarket, retrospective, single center study is to evaluate the clinical outcomes of patients who have received PhotoFix® Decellularized Bovine Pericardium (PhotoFix) as a patch within a cardiac surgical repair or reconstruction procedure. PhotoFix is prepared from bovine pericardium, which is stabilized using a dye-mediated photo-oxidation process and sterilized using aseptic processing techniques.

NCT ID: NCT05313009 Terminated - Clinical trials for Non-Small Cell Lung Cancer

Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Start date: March 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase IB dose expansion trial with safety lead-in evaluating the safety, clinical activity/efficacy of the combination of tarloxotinib and sotorasib in patients with KRAS G12C mutation who have progressed on any small molecule targeting KRAS G12C mutant Non-Small Cell lung cancer.

NCT ID: NCT05312970 Terminated - Varicose Veins Clinical Trials

Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)

VERITAS
Start date: February 10, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.

NCT ID: NCT05312697 Terminated - Clinical trials for Osteogenesis Imperfecta

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Start date: April 28, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).

NCT ID: NCT05312008 Terminated - Clinical trials for Alcohol Use Disorder

Does Oxytocin Alter Tolerance to or Motivation for Alcohol

Start date: January 16, 2022
Phase: Phase 2
Study type: Interventional

This pilot study will seek evidence that oxytocin, compared to placebo, reverses tolerance and alcohol seeking in humans.

NCT ID: NCT05307770 Terminated - Parkinson Disease Clinical Trials

Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this research is to compare the efficacy of immediate versus extended-release melatonin as a supplement affecting the sleep cycle in patients with Parkinson disease and Rapid Eye Movement Sleep Behavior Disorder.

NCT ID: NCT05307679 Terminated - Dup15q Syndrome Clinical Trials

A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

Start date: December 16, 2022
Phase: Phase 2
Study type: Interventional

This study consists of two parts. Part 1 will evaluate the safety, efficacy, and pharmacodynamics of 52-weeks of basmisanil treatment in children and adolescents (aged 2-14 years) with Dup15q syndrome. Part 1 will test the hypothesis that negative allosteric modulation of a GABAA receptor subtype can address excessive receptor function and positively impact core neurodevelopmental disease feature in individuals with Dup15q syndrome. Part 2 is an optional 2-year open-label extension to evaluate long-term safety, tolerability, and to provide supportive evidence of benefit of continued treatment with basmisanil in selected efficacy outcomes.